Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2024-06-20,40.0,40.0,32.474998474121094,32.60499954223633,4642609,0.0,0.0,,,,,,,,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-06-24,33.0,33.775001525878906,31.0,33.099998474121094,893033,0.0,0.0,,,,,,,100.0,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-06-25,33.099998474121094,33.599998474121094,32.0,32.599998474121094,507326,0.0,0.0,,,,,,,47.89722936561817,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-06-26,32.900001525878906,32.900001525878906,30.100000381469727,30.100000381469727,812016,0.0,0.0,,,,,,,12.586212284631955,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-06-27,30.100000381469727,31.299999237060547,30.100000381469727,30.5,339065,0.0,0.0,,,,,,,22.43877237579376,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-06-28,30.700000762939453,32.20000076293945,30.700000762939453,31.0,476774,0.0,0.0,,,,,,,32.65661493513173,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-01,31.899999618530273,32.400001525878906,30.600000381469727,31.5,399415,0.0,0.0,,,,,,,41.02374309163976,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-02,31.5,34.5,31.200000762939453,34.20000076293945,765746,0.0,0.0,,,,,,,65.76197805475263,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-03,34.29999923706055,35.400001525878906,34.099998474121094,35.0,394410,0.0,0.0,,,,,,,69.80361113526021,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-04,35.099998474121094,35.29999923706055,32.79999923706055,33.0,449297,0.0,0.0,32.36049976348877,,,1.9761754026826184,,,52.96923505718805,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-05,33.20000076293945,33.599998474121094,32.29999923706055,33.599998474121094,253619,0.0,0.0,32.45999965667725,,,3.512011181458348,,,56.36878390621523,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-08,33.79999923706055,33.900001525878906,32.599998474121094,33.5,149893,0.0,0.0,32.499999809265134,,,3.0769236818573305,,,55.64683309702092,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-09,33.5,34.900001525878906,32.79999923706055,34.900001525878906,437473,0.0,0.0,32.73000011444092,,,6.630007344486849,,,62.82536277673535,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-10,35.0,35.0,34.099998474121094,35.0,262211,0.0,0.0,33.22000007629394,,,5.358217699030892,,,63.282486412573164,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-11,34.900001525878906,34.900001525878906,34.0,34.20000076293945,200463,0.0,0.0,33.59000015258789,,,1.8160184804422097,,,57.22044306439997,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-12,34.20000076293945,34.29999923706055,33.400001525878906,34.20000076293945,176145,0.0,0.0,33.910000228881835,,,0.8552065234450198,,,57.22044306439997,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-15,34.0,34.400001525878906,33.5,33.79999923706055,325240,0.0,0.0,34.14000015258789,,,-0.995901915664075,,,54.209172868196895,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-16,33.900001525878906,33.900001525878906,33.29999923706055,33.70000076293945,200894,0.0,0.0,34.09000015258789,,,-1.144028711947164,,,53.45185586677767,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-17,33.70000076293945,33.70000076293945,33.20000076293945,33.5,200918,0.0,0.0,33.94000015258789,,,-1.2964058650846602,,,51.890451680323444,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-18,33.400001525878906,33.599998474121094,32.900001525878906,33.0,204731,0.0,0.0,33.94000015258789,,,-2.7695938372475757,,,48.107034978972436,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-19,33.0,33.0,32.5,32.79999923706055,157509,0.0,0.0,33.86000022888184,,,-3.130540415404761,,,46.64209083049685,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-22,32.79999923706055,32.79999923706055,31.600000381469727,31.600000381469727,98883,0.0,0.0,33.67000026702881,,,-6.147905759258703,,,38.97349729971708,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-23,31.600000381469727,32.400001525878906,30.700000762939453,31.700000762939453,135227,0.0,0.0,33.35000019073486,,,-4.947524492829845,,,39.86085851110103,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-24,31.700000762939453,31.899999618530273,31.5,31.5,43019,0.0,0.0,33.000000190734866,,,-4.545455097166965,,,38.65039804855564,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-25,31.5,32.0,31.100000381469727,31.299999237060547,39792,0.0,0.0,32.71000003814697,,,-4.310610820672755,,,37.4264382799329,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-26,31.299999237060547,31.799999237060547,31.299999237060547,31.600000381469727,17712,0.0,0.0,32.45,,,-2.6194133082597113,,,40.47161976048259,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-29,31.600000381469727,32.20000076293945,31.0,31.700000762939453,96756,0.0,0.0,32.24000015258789,,,-1.6749360641832707,,,41.49370780527734,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-30,31.700000762939453,32.900001525878906,31.700000762939453,31.799999237060547,32789,0.0,0.0,32.05,,,-0.7800335817143536,,,42.55585909661891,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-07-31,32.099998474121094,35.29999923706055,32.099998474121094,34.20000076293945,385784,0.0,0.0,32.12000007629395,,,6.475718187126164,,,60.90189796761686,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-01,34.29999923706055,35.20000076293945,33.70000076293945,34.0,100477,0.0,0.0,32.22000007629394,,,5.524518682467984,,,59.204984637796876,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-02,34.5,34.5,31.204999923706055,31.485000610351562,241601,0.0,0.0,32.08850021362305,,,-1.880734840375225,,,42.985373074999146,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-05,29.84000015258789,30.985000610351562,28.959999084472656,29.729999542236328,158065,0.0,0.0,31.901500129699706,,,-6.8068917719695285,,,35.64658577826346,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-06,29.825000762939453,31.0,29.825000762939453,30.0,40277,0.0,0.0,31.73150005340576,,,-5.456722973989745,,,37.41682909187921,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-07,30.0,31.4950008392334,30.0,30.3700008392334,21511,0.0,0.0,31.6185001373291,,,-3.9486354275916824,,,39.85834542332187,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-08,30.295000076293945,30.299999237060547,29.5,30.149999618530273,79469,0.0,0.0,31.503500175476074,,,-4.296349768777229,,,38.88691298174766,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-09,31.719999313354492,33.154998779296875,31.100000381469727,32.915000915527344,366917,0.0,0.0,31.635000228881836,,,4.046153555822972,,,54.045961744191594,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-12,33.400001525878906,33.6150016784668,31.799999237060547,31.915000915527344,87896,0.0,0.0,31.656500244140624,,,0.8165800685265792,,,49.284528716931185,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-13,31.899999618530273,31.899999618530273,30.94499969482422,30.94499969482422,43441,0.0,0.0,31.57100028991699,,,-1.9828342128668697,,,45.131095162677234,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-14,30.94499969482422,31.895000457763672,30.489999771118164,30.895000457763672,27081,0.0,0.0,31.240500259399415,,,-1.1059355604646293,,,44.920949049278356,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-15,31.315000534057617,31.459999084472656,30.549999237060547,31.344999313354492,8744,0.0,0.0,30.975000190734864,32.373875045776366,,1.1945088630872747,-4.320999117540008,,47.299397721293595,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-16,31.344999313354492,31.899999618530273,30.200000762939453,31.565000534057617,44740,0.0,0.0,30.983000183105467,32.3478750705719,,1.8784505939147405,-4.219364902605655,,48.47093987804487,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-19,31.40999984741211,31.545000076293945,31.0,31.0049991607666,46856,0.0,0.0,31.110500144958497,32.295500087738034,,-0.33911696597713437,-3.6692416576929197,,45.68685609474056,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-20,31.0,31.0049991607666,30.125,30.5,17245,0.0,0.0,31.160500144958498,32.24300012588501,,-2.119671192329565,-3.357317795180826,,43.2730382375742,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-21,30.5,31.295000076293945,30.19499969482422,30.600000381469727,51238,0.0,0.0,31.18350009918213,32.25550012588501,,-1.8711809638319172,-3.3234642852199903,,43.905060807721995,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-22,30.594999313354492,30.594999313354492,30.0,30.274999618530273,42518,0.0,0.0,31.19600009918213,32.249875116348264,,-2.952303108487301,-3.2678421648581804,,42.257234097046585,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-23,30.149999618530273,31.19499969482422,29.799999237060547,30.815000534057617,35369,0.0,0.0,30.986000061035156,32.245250129699706,,-0.5518606036297362,-3.9052265484047477,,45.89103384487448,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-26,30.815000534057617,31.40999984741211,30.100000381469727,30.600000381469727,65819,0.0,0.0,30.854500007629394,32.22275013923645,,-0.8248379526381472,-4.246223943315725,,44.68528489041432,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-27,31.0,31.295000076293945,30.350000381469727,30.559999465942383,11659,0.0,0.0,30.81599998474121,32.13175010681152,,-0.830738963283972,-4.094859812168744,,44.45127772925871,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-28,30.559999465942383,31.2450008392334,30.5,30.80500030517578,30543,0.0,0.0,30.806999969482423,32.02687511444092,,-0.006490941372487465,-3.808910924339462,,46.305974457777275,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-29,30.799999237060547,30.860000610351562,30.200000762939453,30.80500030517578,30059,0.0,0.0,30.75300006866455,31.972000122070312,,0.16908996323976488,-3.812711274714039,,46.305974457777275,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-08-30,30.9950008392334,30.9950008392334,30.100000381469727,30.5,16650,0.0,0.0,30.646500015258788,31.894500160217284,,-0.4780317986910277,-3.9129007781572143,,44.176407516442865,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-02,30.450000762939453,31.299999237060547,29.850000381469727,30.885000228881836,39083,0.0,0.0,30.634500122070314,31.82912516593933,,0.8177058734869048,-3.7532449844000033,,47.460999810117144,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-03,30.834999084472656,30.834999084472656,29.204999923706055,29.69499969482422,31165,0.0,0.0,30.554000091552734,31.699000120162964,,-2.811417143924153,-3.6121014046809745,,39.68792371764688,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-04,29.19499969482422,29.19499969482422,28.399999618530273,28.725000381469727,38745,0.0,0.0,30.366500091552734,31.542125129699706,,-5.405626941313645,-3.727158627748949,,34.69925021919505,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-05,28.725000381469727,30.43000030517578,28.5,29.0,38634,0.0,0.0,30.239000129699708,31.41212511062622,,-4.097358128196853,-3.734624692837682,,37.112682511920475,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-06,28.954999923706055,29.295000076293945,28.405000686645508,28.704999923706055,58443,0.0,0.0,30.02800006866455,31.274750089645387,,-4.4058883106873985,-3.9864427930108954,,35.59298858740192,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-09,28.704999923706055,29.395000457763672,28.385000228881836,28.5,24103,0.0,0.0,29.818000030517577,31.142250108718873,,-4.420149001169277,-4.252262034947006,,34.53469619262009,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-10,28.5,28.7450008392334,27.80500030517578,27.8700008392334,57804,0.0,0.0,29.54900016784668,30.996500110626222,,-5.6820850758945785,-4.669881882191311,,31.440799840167685,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-11,27.80500030517578,27.80500030517578,27.0,27.020000457763672,19995,0.0,0.0,29.170500183105467,30.834500122070313,,-7.372172955016004,-5.396552343567295,,27.81950893908956,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-12,27.020000457763672,28.485000610351562,27.010000228881836,27.729999542236328,15275,0.0,0.0,28.863000106811523,30.70275011062622,,-3.9254428173868603,-5.992134245908998,,34.595895647009826,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-13,27.729999542236328,28.235000610351562,27.28499984741211,27.80500030517578,20391,0.0,0.0,28.5935001373291,30.5778751373291,,-2.757619138497584,-6.489577811041222,,35.28702964960914,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-16,27.80500030517578,28.354999542236328,27.614999771118164,28.0,25736,0.0,0.0,28.30500011444092,30.487875127792357,,-1.0775485363284305,-7.159813546210564,,37.14670960138333,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-17,28.485000610351562,28.530000686645508,28.0049991607666,28.4950008392334,17659,0.0,0.0,28.185000228881837,30.407750129699707,,1.0998779770592189,-7.3098137525369795,,41.72482903051404,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-18,28.4950008392334,28.4950008392334,27.844999313354492,28.0049991607666,11543,0.0,0.0,28.113000106811523,30.32037510871887,,-0.38416727362638725,-7.280170492589319,,38.71838804280721,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-19,27.94499969482422,28.395000457763672,27.94499969482422,28.104999542236328,15497,0.0,0.0,28.023500061035158,30.240500116348265,,0.2908254894059081,-7.331228143659499,,39.67371811609736,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-20,28.274999618530273,28.395000457763672,27.905000686645508,27.905000686645508,5997,0.0,0.0,27.943500137329103,30.14812512397766,,-0.1377760498662965,-7.31264374677534,,38.384892570519725,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-23,28.600000381469727,28.985000610351562,28.0,28.0,127308,0.0,0.0,27.893500137329102,30.055625104904173,,0.38180888790063283,-7.193744798281627,,39.39205252127247,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-24,28.010000228881836,28.579999923706055,27.5,28.0049991607666,24391,0.0,0.0,27.90699996948242,29.960750102996826,,0.35116347651609886,-6.854802120955507,,39.44814440367469,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-25,28.0049991607666,28.4950008392334,27.670000076293945,28.0049991607666,39331,0.0,0.0,28.005499839782715,29.805875062942505,,-0.0017877881808131507,-6.040336743537476,,39.44814440367469,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-26,28.200000762939453,28.5,28.0,28.0,30579,0.0,0.0,28.032499885559083,29.655875062942506,,-0.11593645123254147,-5.474042407913856,,39.405848287922105,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-27,28.40999984741211,28.415000915527344,27.700000762939453,28.0,4580,0.0,0.0,28.051999855041505,29.568750047683714,,-0.18536951130120302,-5.12957155847386,,39.405848287922105,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-09-30,28.0,28.5,27.510000228881836,28.030000686645508,30907,0.0,0.0,28.054999923706056,29.526250076293945,,-0.08910795625924887,-4.982854743783149,,39.854675558690865,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-01,28.100000381469727,28.68000030517578,27.959999084472656,27.959999084472656,31395,0.0,0.0,28.001499748229982,29.475250053405762,,-0.14820871785608183,-4.999958617842138,,39.12642609132791,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-02,27.959999084472656,28.46500015258789,27.204999923706055,27.889999389648438,8183,0.0,0.0,27.989999771118164,29.41325001716614,,-0.3572718195336079,-4.838806474012012,,38.37136686724507,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-03,27.889999389648438,28.614999771118164,27.809999465942383,28.399999618530273,24942,0.0,0.0,28.01949977874756,29.36950001716614,,1.3579822723006614,-4.596606130950547,,46.47575602193596,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-04,28.399999618530273,29.5,28.0049991607666,29.21500015258789,94296,0.0,0.0,28.150499725341795,29.276999998092652,,3.781461919440829,-3.847731232107956,,56.353529950541535,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-07,29.21500015258789,29.5,28.010000228881836,28.704999923706055,59945,0.0,0.0,28.220999717712402,29.19674997329712,,1.7150356501718058,-3.341982434610438,,50.12022066825197,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-08,28.704999923706055,28.9950008392334,28.405000686645508,28.405000686645508,11212,0.0,0.0,28.260999870300292,29.13324999809265,,0.509539000764609,-2.9940021379333412,,46.83826427593033,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-09,29.399999618530273,29.399999618530273,28.155000686645508,28.155000686645508,15703,0.0,0.0,28.276000022888184,29.064750003814698,,-0.42792239406115473,-2.7137683304449283,,44.23855204504888,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-10,28.165000915527344,29.200000762939453,28.165000915527344,28.799999237060547,26180,0.0,0.0,28.35599994659424,29.001125001907347,,1.565803679300811,-2.2244828615120285,,51.688874256613765,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-11,28.799999237060547,29.5,28.239999771118164,28.475000381469727,19671,0.0,0.0,28.40349998474121,28.92387499809265,,0.2517309372680414,-1.799119286007687,,48.19467366130371,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-14,28.485000610351562,28.989999771118164,28.0,28.0,19544,0.0,0.0,28.40049991607666,28.848750019073485,,-1.4101861490471537,-1.5537938479152846,,43.5598429594329,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-15,28.0,28.34000015258789,27.0,27.780000686645508,14758,0.0,0.0,28.382500076293944,28.780750036239624,,-2.1227847724086315,-1.3837372530049388,,41.56602555891916,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-16,27.780000686645508,27.780000686645508,27.299999237060547,27.485000610351562,16717,0.0,0.0,28.342000198364257,28.70287504196167,,-3.0237794863262892,-1.257277687582992,,38.988955843145504,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-17,27.485000610351562,27.485000610351562,27.100000381469727,27.125,13441,0.0,0.0,28.21450023651123,28.624125051498414,,-3.8614904654641147,-1.4310474617135576,,36.05146590499561,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-18,27.104999542236328,27.635000228881836,27.104999542236328,27.299999237060547,20591,0.0,0.0,28.023000144958495,28.536250019073485,,-2.5800267785675333,-1.7985890709954413,,38.477980821872215,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-21,27.295000076293945,27.299999237060547,26.875,27.19499969482422,43661,0.0,0.0,27.87200012207031,28.45112500190735,,-2.4289624866570403,-2.035507839490406,,37.55714775058185,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-22,27.19499969482422,27.19499969482422,26.649999618530273,26.649999618530273,14539,0.0,0.0,27.69650001525879,28.353375005722047,,-3.778457191890557,-2.3167435634406597,,33.12586283464658,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-23,26.655000686645508,27.0,25.899999618530273,25.905000686645508,35966,0.0,0.0,27.47150001525879,28.23087501525879,,-5.702270817913783,-2.6898741168651568,,28.223632136822985,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-24,25.90999984741211,27.405000686645508,25.639999389648438,26.0,90470,0.0,0.0,27.191500091552733,28.110750007629395,,-4.3818843665888165,-3.2701009963347594,,29.65325037870636,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-25,26.0,26.4950008392334,25.709999084472656,25.975000381469727,11311,0.0,0.0,26.941500091552733,27.997625017166136,,-3.5874012463992075,-3.7721946949638165,,29.486807980800407,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-28,25.530000686645508,26.280000686645508,25.530000686645508,25.530000686645508,29767,0.0,0.0,26.694500160217284,27.86375002861023,,-4.362319828363844,-4.196311936449226,,26.622310655925503,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-29,25.530000686645508,27.049999237060547,25.530000686645508,25.829999923706055,12110,0.0,0.0,26.49950008392334,27.767125034332274,,-2.526463360052052,-4.565200570248437,,31.4565873413311,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-30,26.450000762939453,26.450000762939453,25.4950008392334,25.81999969482422,15391,0.0,0.0,26.332999992370606,27.69450001716614,,-1.9481270561463475,-4.916138669958372,,31.382366199629914,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-10-31,25.81999969482422,26.399999618530273,25.625,25.7549991607666,39436,0.0,0.0,26.195999908447266,27.613374996185303,,-1.6834659842034048,-5.132929560163663,,30.872473123362838,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-01,25.625,25.719999313354492,24.610000610351562,24.610000610351562,51645,0.0,0.0,25.927000045776367,27.511000013351442,,-5.079644513825464,-5.757696800575548,,23.598771018040495,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-04,24.604999542236328,25.155000686645508,24.024999618530273,24.1299991607666,64439,0.0,0.0,25.620499992370604,27.401749992370604,,-5.817610241985329,-6.5004972328261825,,21.329968956362507,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-05,24.1299991607666,24.1299991607666,23.229999542236328,23.594999313354492,41568,0.0,0.0,25.314999961853026,27.294874954223634,,-6.794393249418879,-7.253651081717962,,19.12316940599905,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-06,23.584999084472656,23.584999084472656,22.600000381469727,22.979999542236328,60654,0.0,0.0,25.02249984741211,27.19387493133545,,-8.162654881131001,-7.984794698828555,,16.95197396016229,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-07,22.975000381469727,23.19499969482422,22.219999313354492,23.19499969482422,33394,0.0,0.0,24.74199981689453,27.080499935150147,,-6.252526608677673,-8.635365387846008,,20.35635882777933,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-08,23.200000762939453,24.625,22.690000534057617,23.0049991607666,59376,0.0,0.0,24.44499969482422,26.960499906539916,,-5.890777467927361,-9.330317391872626,,19.592014295634883,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-11,23.0049991607666,23.0049991607666,22.600000381469727,22.795000076293945,37399,0.0,0.0,24.17149963378906,26.830374908447265,,-5.694721379930118,-9.909944545057716,,18.75385441555258,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-12,23.0,23.0,21.5,21.704999923706055,69894,0.0,0.0,23.758999633789063,26.66062488555908,,-8.645143910696877,-10.88356054753129,,15.134644018261326,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-13,21.71500015258789,23.46500015258789,21.209999084472656,22.399999618530273,88328,0.0,0.0,23.41699962615967,26.520499897003173,,-4.342998778089748,-11.70226912349492,,25.06471579946603,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-14,22.600000381469727,23.31999969482422,20.719999313354492,21.0,104083,0.0,0.0,22.941499710083008,26.342874908447264,,-8.46282821357882,-12.911936188382958,,19.99045656669891,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-15,20.989999771118164,21.0,20.5,20.764999389648438,153712,0.0,0.0,22.556999588012694,26.16437487602234,,-7.944319861213129,-13.787355154108921,,19.284710061849125,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-18,20.700000762939453,20.799999237060547,20.145000457763672,20.225000381469727,27086,0.0,0.0,22.16649971008301,25.969999885559083,,-8.758709557243002,-14.64574583071544,,17.735277540299464,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-19,20.25,20.479999542236328,19.214000701904297,19.36400032043457,61038,0.0,0.0,21.743399810791015,25.75397491455078,,-10.943088528297098,-15.57264506572857,,15.585144685729418,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-20,19.802000045776367,20.5,19.802000045776367,20.145000457763672,87750,0.0,0.0,21.45989990234375,25.55747494697571,,-6.1272394119437195,-16.032785136768126,,24.523758659434606,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-21,20.299999237060547,20.485000610351562,19.304000854492188,19.6560001373291,43595,0.0,0.0,21.10599994659424,25.348874950408934,,-6.87008344989177,-16.737922342175775,,22.88946652908716,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-22,19.899999618530273,20.309999465942383,19.850000381469727,20.010000228881836,35545,0.0,0.0,20.806500053405763,25.149124956130983,,-3.8281297790569546,-17.26749900960889,,26.697830087777803,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-25,20.100000381469727,20.514999389648438,19.79800033569336,19.865999221801758,115424,0.0,0.0,20.513599967956544,24.945024919509887,,-3.1569336789562885,-17.764764580721895,,26.132435790810376,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-26,19.799999237060547,20.270000457763672,19.115999221801758,19.898000717163086,51435,0.0,0.0,20.332900047302246,24.74347496032715,,-2.138894742645736,-17.82520409965322,,26.504933044430047,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-27,19.600000381469727,20.100000381469727,19.356000900268555,19.75,24344,0.0,0.0,20.067900085449217,24.539974975585938,,-1.5841223251839862,-18.22363264259988,,25.85554947028757,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-28,19.65999984741211,19.756000518798828,19.302000045776367,19.59600067138672,79617,0.0,0.0,19.92750015258789,24.31987500190735,,-1.6635276811583424,-18.0608446752912,,25.164664998059095,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-11-29,19.5,21.0,19.003999710083008,20.0,294409,0.0,0.0,19.851000213623045,24.089499998092652,,0.7505908255177047,-17.594801821562093,,30.417549804532626,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-02,19.468000411987305,20.049999237060547,19.304000854492188,19.757999420166016,50280,0.0,0.0,19.804300117492676,23.86582498550415,,-0.23379113148141267,-17.018162458152617,,29.09989096990097,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-03,19.600000381469727,19.601999282836914,18.989999771118164,19.00200080871582,72362,0.0,0.0,19.7681001663208,23.63074998855591,,-3.8754323944098266,-16.345862167327507,,25.39841718781271,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-04,19.003999710083008,20.0,18.812000274658203,19.81999969482422,264785,0.0,0.0,19.735600090026857,23.422374963760376,,0.4276515758951367,-15.74039728865147,,35.02835681013177,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-05,20.075000762939453,20.295000076293945,19.5,19.50200080871582,109219,0.0,0.0,19.72020015716553,23.18992500305176,28.18830835024516,-1.1064763375153857,-14.962208137497726,-17.73211533337696,33.2324042752643,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-06,19.506000518798828,20.094999313354492,19.506000518798828,19.63800048828125,68794,0.0,0.0,19.68300018310547,22.969000005722044,28.080250024795532,-0.22862213283341226,-14.306238067821694,-18.202295259337546,34.77269082239927,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-09,19.663999557495117,19.757999420166016,19.302000045776367,19.5,34758,0.0,0.0,19.646400260925294,22.756500005722046,27.966916704177855,-0.7451760067032178,-13.666863287477108,-18.630644034054164,33.91764594724938,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-10,19.5,21.485000610351562,19.479999542236328,21.385000228881836,282694,0.0,0.0,19.795100212097168,22.596624994277953,27.87345838546753,8.031785642656406,-12.397978825998143,-18.93139099646413,51.471216868208224,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-11,21.424999237060547,23.479999542236328,21.010000228881836,23.34000015258789,150467,0.0,0.0,20.154100227355958,22.49299998283386,27.817125050226846,15.807701109412886,-10.398345072968915,-19.139738768041976,62.57481922654176,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-12,23.825000762939453,24.700000762939453,23.299999237060547,24.530000686645508,74852,0.0,0.0,20.647500228881835,22.428125,27.767375055948893,18.80373127364256,-7.939249362655889,-19.22850123639976,67.45595732141751,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-13,24.649999618530273,24.649999618530273,23.600000381469727,23.600000381469727,113434,0.0,0.0,21.00750026702881,22.33562502861023,27.70570839246114,12.340831043614624,-5.946217130168484,-19.382588193673964,60.78380864684767,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-16,23.850000381469727,23.850000381469727,21.9950008392334,22.184999465942383,69147,0.0,0.0,21.250200271606445,22.210375022888183,27.628083388010662,4.399013573462524,-4.3230911242708,-19.609425268614615,52.30647675966674,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-17,22.0049991607666,22.0049991607666,20.834999084472656,21.475000381469727,134960,0.0,0.0,21.497500228881837,22.08100004196167,27.52204171816508,-0.10466262203770835,-2.6425425115301735,-19.769760295843962,48.64077196790385,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-18,20.815000534057617,21.475000381469727,20.049999237060547,20.200000762939453,224013,0.0,0.0,21.53550033569336,21.93837504386902,27.398708391189576,-6.201386324609435,-1.8363926561108184,-19.92916333631406,42.835261749470256,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-19,19.889999389648438,20.030000686645508,19.5,19.658000946044922,96891,0.0,0.0,21.55110034942627,21.779825067520143,27.28752506573995,-8.784235480726842,-1.0501678382851893,-20.18394847077882,40.61598873081846,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-20,19.68199920654297,20.780000686645508,19.29199981689453,20.295000076293945,75418,0.0,0.0,21.61680030822754,21.637825059890748,27.17665007909139,-6.114689561296938,-0.09716665887174372,-20.38082325482047,44.270417336957756,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-23,20.295000076293945,20.93000030517578,20.0,20.049999237060547,54907,0.0,0.0,21.671800231933595,21.500825023651124,27.064566739400227,-7.483462275936402,0.7952030124164828,-20.557290901130457,43.170029668000666,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-27,19.99799919128418,20.889999389648438,19.402000427246094,20.5,71842,0.0,0.0,21.58330020904541,21.367575025558473,26.94456672668457,-5.019159250684972,1.0095913234370413,-20.698019595924396,45.83318068820357,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2024-12-30,20.774999618530273,21.649999618530273,20.600000381469727,21.3799991607666,155488,0.0,0.0,21.387300109863283,21.25657501220703,26.83106671969096,-0.034136843169438186,0.6149866456904804,-20.776258229766484,50.69871251378764,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-02,21.31999969482422,22.614999771118164,21.31999969482422,22.200000762939453,63391,0.0,0.0,21.154300117492674,21.167700052261353,26.731066719690958,4.9432060604173795,-0.06330368786214287,-20.81236310457993,54.77524004644202,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-03,22.209999084472656,23.260000228881836,22.209999084472656,22.899999618530273,76165,0.0,0.0,21.08430004119873,21.12495002746582,26.63690004348755,8.611618947670378,-0.19242642569208337,-20.69291098822644,57.97014076428084,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-07,23.0,23.4950008392334,21.5,21.760000228881836,71333,0.0,0.0,21.041800117492677,21.0657000541687,26.536566718419394,3.4132066048479257,-0.11345427217973893,-20.616331880089405,51.5794241754765,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-08,21.94499969482422,22.03499984741211,20.30500030517578,21.165000915527344,163233,0.0,0.0,21.010800170898438,21.004950094223023,26.432108386357626,0.733911813803671,0.027850942988072044,-20.53244566345572,48.569827533208375,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-09,21.100000381469727,21.399999618530273,20.549999237060547,21.165000915527344,28904,0.0,0.0,21.107300186157225,20.959575128555297,26.329316727320354,0.27336859219901755,0.7048094090450697,-20.394534557720586,48.569827533208375,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-10,21.049999237060547,21.165000915527344,19.49799919128418,20.114999771118164,316118,0.0,0.0,21.15300006866455,20.882575130462648,26.221941725413004,-4.907106765834365,1.2949788831714404,-20.36220906469221,43.38841400876575,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-13,20.479999542236328,20.479999542236328,19.351999282836914,19.52400016784668,34509,0.0,0.0,21.075900077819824,20.79555015563965,26.111308399836222,-7.363386162597899,1.3481245751228448,-20.358069242634794,40.75314518021626,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-14,19.736000061035156,20.475000381469727,19.00200080871582,19.253999710083008,45882,0.0,0.0,20.99630012512207,20.707025146484376,26.008425060908,-8.298130645191144,1.3969895559179604,-20.383394619276274,39.570684503911664,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-15,19.398000717163086,19.729999542236328,19.00200080871582,19.18000030517578,68283,0.0,0.0,20.864300155639647,20.643900156021118,25.90409172375997,-8.072640049748312,1.0676277154646368,-20.30641191296452,39.23468076612697,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-16,19.003999710083008,19.333999633789062,18.805999755859375,19.0,92788,0.0,0.0,20.626300239562987,20.558900165557862,25.7999250570933,-7.88459501061468,0.327838908999809,-20.314108974880522,38.380959555483926,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-17,19.0,19.31800079345703,18.5,18.700000762939453,54107,0.0,0.0,20.27630023956299,20.501400184631347,25.69492506980896,-7.774098124409651,-1.097973519082378,-20.212259312170186,36.93833008979786,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-20,18.739999771118164,19.00200080871582,18.700000762939453,18.753999710083008,14512,0.0,0.0,19.86170024871826,20.451125192642213,25.58787506421407,-5.577068049381808,-2.8821149857124317,-20.074937284479166,37.39447356522981,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-21,18.75200080871582,19.600000381469727,18.700000762939453,19.464000701904297,30061,0.0,0.0,19.632100296020507,20.432100200653075,25.485908397038777,-0.8562486518586326,-3.9154071132002235,-19.82981386283609,43.21093757909833,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-22,19.464000701904297,19.488000869750977,18.50200080871582,18.540000915527344,57614,0.0,0.0,19.369600296020508,20.411500215530396,25.375408411026,-4.2829969014053715,-5.104474970032544,-19.561884936357167,38.23266630024728,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-23,18.700000762939453,19.36199951171875,18.34000015258789,19.0,51872,0.0,0.0,19.153100204467773,20.382875204086304,25.248741738001506,-0.7993494673622582,-6.03337354178565,-19.271718901507313,41.825891101030194,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-24,18.99799919128418,19.1560001373291,18.676000595092773,18.68199920654297,34174,0.0,0.0,19.009800148010253,20.35852518081665,25.121091731389363,-1.7243786831793455,-6.624866098244027,-18.958437799985344,40.08963587757686,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-27,19.08799934387207,19.08799934387207,18.00200080871582,18.20400047302246,56987,0.0,0.0,18.87780017852783,20.313375186920165,25.010416730244955,-3.5692702493576034,-7.067141699409484,-18.78034098346184,37.56534732807245,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-28,18.3799991607666,18.591999053955078,18.077999114990234,18.079999923706055,45722,0.0,0.0,18.760400199890135,20.268725204467774,24.913333400090536,-3.6267897749221,-7.441637248331549,-18.643062014358478,36.915961779264855,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-29,18.049999237060547,18.989999771118164,18.00200080871582,18.43000030517578,46701,0.0,0.0,18.685400199890136,20.23202519416809,24.816916735967002,-1.3668419834853547,-7.644439839486619,-18.474863701154526,40.06532642214122,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-30,18.43400001525879,19.073999404907227,18.011999130249023,19.073999404907227,118678,0.0,0.0,18.69280014038086,20.215125179290773,24.72278339068095,2.0392839043032693,-7.530623854209155,-18.23281036021737,45.460620029042744,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-01-31,19.270000457763672,19.270000457763672,18.4060001373291,18.983999252319336,28068,0.0,0.0,18.721199989318848,20.19982514381409,24.62973338762919,1.4037522335663588,-7.319989871041279,-17.98601785125339,44.852946130208245,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-03,18.50200080871582,19.697999954223633,18.00200080871582,19.697999954223633,72388,0.0,0.0,18.81560001373291,20.19227514266968,24.51959171295166,4.689725227187469,-6.817830676383867,-17.64840385982536,50.50535440105049,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-04,19.690000534057617,19.690000534057617,18.860000610351562,18.986000061035156,34800,0.0,0.0,18.767799949645998,20.172975158691408,24.411850039164225,1.1626302069213736,-6.96563198036755,-17.364005078158105,45.49736474753961,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-05,18.986000061035156,19.082000732421875,18.20199966430664,18.309999465942383,22761,0.0,0.0,18.7447998046875,20.15567512512207,24.30655837059021,-2.319578460562626,-6.9998911555984185,-17.077215055219472,41.30919246420026,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-06,18.219999313354492,18.399999618530273,18.006000518798828,18.3439998626709,39170,0.0,0.0,18.67919979095459,20.118775129318237,24.201966698964437,-1.7945090369771273,-7.155382617035238,-16.871321328695625,41.60037808224251,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-07,18.398000717163086,18.399999618530273,18.00200080871582,18.354000091552734,45082,0.0,0.0,18.646399879455565,20.09007511138916,24.09370837211609,-1.5681299864484515,-7.186012117571278,-16.61692421478952,41.69200826616213,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-10,18.350000381469727,18.350000381469727,17.639999389648438,17.700000762939453,52369,0.0,0.0,18.595999908447265,20.041625118255617,23.97816670735677,-4.818235910513221,-7.213113713476026,-16.417191677516275,37.54329900475399,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-11,17.700000762939453,17.700000762939453,17.290000915527344,17.697999954223633,20914,0.0,0.0,18.557799911499025,19.996575117111206,23.867275047302247,-4.633092076516202,-7.195108148199895,-16.217603067462665,37.53099452630474,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-12,17.59600067138672,17.600000381469727,17.077999114990234,17.149999618530273,62038,0.0,0.0,18.429799842834473,19.890700101852417,23.75602504412333,-6.944189493201619,-7.344639713721741,-16.2709246815982,34.222694312231866,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-13,17.163999557495117,17.215999603271484,16.950000762939453,16.950000762939453,29262,0.0,0.0,18.217399978637694,19.730950117111206,23.642275047302245,-6.957080687608734,-7.670944021904556,-16.543775598437385,33.07673590437487,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-14,16.950000762939453,16.950000762939453,16.562000274658203,16.898000717163086,40930,0.0,0.0,18.00880012512207,19.540150117874145,23.53080005645752,-6.1680922673434155,-7.8369407784195415,-16.95926160185202,32.769490605543936,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-17,16.898000717163086,17.700000762939453,16.775999069213867,17.600000381469727,79289,0.0,0.0,17.79900016784668,19.390150117874146,23.420675055185953,-1.118039128604754,-8.205970249609985,-17.20926031301281,40.768451104493224,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-18,17.639999389648438,17.799999237060547,17.200000762939453,17.299999237060547,53450,0.0,0.0,17.630400085449217,19.2680251121521,23.309841712315876,-1.874040559416221,-8.499184618926266,-17.33952829901999,38.65199273735057,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-19,17.422000885009766,17.423999786376953,16.850000381469727,17.077999114990234,41327,0.0,0.0,17.507200050354005,19.15810008049011,23.197491709391276,-2.4515681212832865,-8.61724295833135,-17.413053443471462,37.116432933782775,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-20,16.562000274658203,17.04199981689453,15.371999740600586,15.699999809265137,352988,0.0,0.0,17.24280004501343,19.045600056648254,23.071616705258688,-8.947504069644799,-9.465703397491652,-17.45008466482016,29.32789120292398,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-21,15.899999618530273,16.00200080871582,15.210000038146973,15.996000289916992,112648,0.0,0.0,17.007000064849855,18.954050040245058,22.9482083717982,-5.944609696464938,-10.272474596516519,-17.405098763447228,32.59964204826359,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-24,16.299999237060547,16.299999237060547,14.604000091552734,15.29800033569336,102788,0.0,0.0,16.766800022125246,18.82912504673004,22.82152504126231,-8.76016702348497,-10.952845761481358,-17.494010533099054,29.170229871499032,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-25,15.0,15.001999855041504,14.449999809265137,15.0,105715,0.0,0.0,16.49700002670288,18.70287506580353,22.68915003935496,-9.07437730666037,-11.794309865940797,-17.56908022837844,27.824433870752046,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-26,15.0,15.279999732971191,14.538000106811523,15.097999572753906,145898,0.0,0.0,16.291800022125244,18.567825055122377,22.567508371671043,-7.327615412355204,-12.257897875708588,-17.723194119070147,28.98476783693461,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-27,14.916000366210938,15.355999946594238,14.5,15.02400016784668,57320,0.0,0.0,16.099199962615966,18.408925080299376,22.45333336989085,-6.678591465824471,-12.546767981337496,-18.012507198663368,28.610734304448158,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-02-28,14.62399959564209,14.965999603271484,14.020000457763672,14.579999923706055,43661,0.0,0.0,15.867399883270263,18.21842505931854,22.3331667025884,-8.113490357809498,-12.904656513356255,-18.424353778691685,26.40868445920472,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-03,14.100000381469727,15.0,14.083999633789062,14.083999633789062,387283,0.0,0.0,15.515799808502198,17.998025059700012,22.21132503350576,-9.228013975332109,-13.791653489558966,-18.96915185136406,24.170635348276903,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-04,14.100000381469727,14.359999656677246,13.600000381469727,14.133999824523926,94536,0.0,0.0,15.199199867248534,17.807375049591066,22.09160836537679,-7.008263935129361,-14.64660105759061,-19.393034879706697,24.861920690324794,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-05,14.697999954223633,14.699999809265137,14.13599967956543,14.14799976348877,34961,0.0,0.0,14.906199932098389,17.6319500207901,21.977258356412253,-5.086475238916812,-15.45915276233053,-19.771839895372267,25.067901608819724,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-06,14.0,14.300000190734863,13.600000381469727,13.696000099182129,31867,0.0,0.0,14.705799961090088,17.44522500038147,21.866225020090738,-6.866677532536669,-15.703007781392783,-20.218396251054962,22.88646649165524,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-07,13.89799976348877,14.338000297546387,13.105999946594238,13.288000106811523,73330,0.0,0.0,14.434999942779541,17.274550008773804,21.74587502479553,-7.945963564355625,-16.437765756862238,-20.56171577792726,21.1014457893083,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-10,13.687999725341797,13.748000144958496,12.649999618530273,12.708000183105469,63130,0.0,0.0,14.175999927520753,17.104150009155273,21.620066690444947,-10.355528724046932,-17.119529939033395,-20.887616795768242,18.8506166081862,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-11,12.699999809265137,13.0,11.755999565124512,12.25,142949,0.0,0.0,13.900999927520752,16.9290500164032,21.488816690444946,-11.876842933091135,-17.886710039538272,-21.21925436717629,17.28289410586069,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-12,12.25,12.57800006866455,11.600000381469727,11.913999557495117,78618,0.0,0.0,13.582599925994874,16.74739999771118,21.350641679763793,-12.284837789459797,-18.89726209530334,-21.56020297233305,16.21732474170743,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-13,11.90999984741211,12.07800006866455,11.368000030517578,11.54800033569336,77535,0.0,0.0,13.234999942779542,16.561100006103516,21.213500022888184,-12.746502564259837,-20.083811232938366,-21.931317376976867,15.123512164621928,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-14,11.54800033569336,11.600000381469727,10.803999900817871,11.600000381469727,98288,0.0,0.0,12.936999988555907,16.383599996566772,21.07595836321513,-10.334695897572027,-21.03689060238964,-22.26403319736175,15.990474990661696,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-17,11.5,12.0,11.40999984741211,11.654000282287598,42172,0.0,0.0,12.694000053405762,16.206100010871886,20.940533359845478,-8.192845176797805,-21.67146910799036,-22.608943466798728,16.93929235067756,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-18,11.842000007629395,12.489999771118164,11.5,12.399999618530273,62254,0.0,0.0,12.520600032806396,16.029499983787538,20.810533356666564,-0.9632159318253591,-21.890264540566413,-22.9741030224362,28.88814635045516,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-19,13.0,13.289999961853027,12.300000190734863,12.920000076293945,61056,0.0,0.0,12.397800064086914,15.888999962806702,20.684825030962624,4.212037696266004,-21.972433173214554,-23.185233914123835,35.81900499953075,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-20,13.498000144958496,13.498000144958496,12.291999816894531,12.47599983215332,15678,0.0,0.0,12.275800037384034,15.725899958610535,20.555416703224182,1.6308492657065865,-21.93896648399724,-23.495105034071734,32.87290618707007,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-21,12.477999687194824,12.663999557495117,12.0,12.394000053405762,80389,0.0,0.0,12.186400032043457,15.568699979782105,20.42536670366923,1.7035385414595976,-21.724999210794643,-23.777623160198484,32.34380461577793,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-24,13.447999954223633,13.447999954223633,11.350000381469727,11.631999969482422,202185,0.0,0.0,12.078800010681153,15.404399967193603,20.288966703414918,-3.6990432890985088,-21.588636776472335,-24.074990154127335,27.856776127631065,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-25,12.0,12.251999855041504,11.604000091552734,11.803999900817871,31035,0.0,0.0,12.03420000076294,15.2474999666214,20.153750030199685,-1.9128824511016513,-21.07427429344323,-24.344104974143484,30.2102915252851,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-26,12.031999588012695,12.140000343322754,11.569999694824219,12.0,26825,0.0,0.0,12.042800045013427,15.086749958992005,20.02075003782908,-0.3553994490770411,-20.17631313737206,-24.64443174963133,32.896735856417266,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-27,12.001999855041504,12.227999687194824,11.70199966430664,11.925999641418457,29155,0.0,0.0,12.080599975585937,14.908049964904786,19.88771670659383,-1.2797405301054288,-18.965927777106877,-25.03890625130447,32.3897954794342,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-28,11.800000190734863,12.0,11.637999534606934,11.699999809265137,21540,0.0,0.0,12.090599918365479,14.72594997882843,19.748550041516623,-3.23060982695346,-17.895959610427894,-25.4327535547135,30.82736926753634,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-03-31,11.899999618530273,12.0,11.461999893188477,11.895999908447266,36597,0.0,0.0,12.114799880981446,14.53089997768402,19.604225039482117,-1.8060551943385021,-16.627325908327258,-25.878733036274703,33.8094550033,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-01,11.501999855041504,12.0,11.501999855041504,12.0,12574,0.0,0.0,12.074799919128418,14.356249976158143,19.465016706784567,-0.6194712925215702,-15.891685229907512,-26.245889266798084,35.40083841900844,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-02,11.685999870300293,12.185999870300293,11.513999938964844,11.779999732971191,26421,0.0,0.0,11.960799884796142,14.192999982833863,19.326475032170613,-1.5116058588587615,-15.727471998432469,-26.56187970538668,33.562572715940746,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-03,11.82800006866455,11.998000144958496,11.336000442504883,11.399999618530273,11142,0.0,0.0,11.853199863433838,14.019399976730346,19.186850023269653,-3.823442193880919,-15.451446687390375,-26.93224807757535,30.606261046462876,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-04,11.699999809265137,11.699999809265137,10.32800006866455,10.8100004196167,58034,0.0,0.0,11.694799900054932,13.830799984931947,19.03693336645762,-7.565751342475526,-15.443792746653076,-27.34754217661281,26.677209306689306,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-07,11.0,11.0,9.600000381469727,10.680000305175781,67312,0.0,0.0,11.599599933624267,13.655299973487853,18.888641699155173,-7.927856423589251,-15.05422834983329,-27.706289361724668,25.88859800331514,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-08,10.979999542236328,11.079999923706055,10.680000305175781,11.020000457763672,19100,0.0,0.0,11.521199989318848,13.488349986076354,18.74714170296987,-4.350237232404887,-14.584066982159714,-28.05116534677088,31.584919642789814,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-09,10.399999618530273,11.5,10.220000267028809,10.819999694824219,11916,0.0,0.0,11.40319995880127,13.330099987983704,18.60580836137136,-5.114356198997661,-14.455255631386263,-28.35516883179809,30.118429911320973,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-10,11.380000114440918,11.65999984741211,10.920000076293945,11.180000305175781,32535,0.0,0.0,11.328600025177002,13.185849976539611,18.469933358828225,-1.3117218338626848,-14.08517429416417,-28.6091090835633,35.88862637324597,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-11,11.199999809265137,11.199999809265137,10.199999809265137,11.0,17248,0.0,0.0,11.258600044250489,13.038399958610535,18.335558358828226,-2.2969111899711736,-13.650447294222397,-28.890085027965394,34.360894650279505,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-14,10.880000114440918,11.15999984741211,10.4399995803833,10.699999809265137,32509,0.0,0.0,11.139000034332275,12.86589994430542,18.197225030263265,-3.941109827758916,-13.422301723537721,-29.297461987151756,31.921894164808506,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-15,10.619999885559082,10.619999885559082,10.0,10.199999809265137,90297,0.0,0.0,10.95900001525879,12.688399958610535,18.05560003121694,-6.925816269156465,-13.629771673284537,-29.72595794837541,28.314530361135397,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-16,10.65999984741211,10.65999984741211,9.949999809265137,10.100000381469727,35732,0.0,0.0,10.791000080108642,12.513949990272522,17.9176833709081,-6.403481544890864,-13.76823394294513,-30.15866096511844,27.64174136010334,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-17,10.079999923706055,10.319999694824219,10.039999961853027,10.180000305175781,27217,0.0,0.0,10.669000148773193,12.375950002670288,17.78664170106252,-4.583370857424172,-13.79247535363989,-30.41997353592058,29.093296561540868,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-22,10.119999885559082,10.300000190734863,10.0,10.15999984741211,30336,0.0,0.0,10.604000091552734,12.230049991607666,17.654641699790954,-4.187101474040165,-13.295529463663167,-30.726150099367462,28.937005520803496,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-23,10.199999809265137,10.979999542236328,10.079999923706055,10.899999618530273,75060,0.0,0.0,10.626000022888183,12.120099973678588,17.529016693433125,2.578577028532851,-12.327455664847363,-30.85693176264059,41.466224976963225,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-24,10.399999618530273,10.859999656677246,10.319999694824219,10.420000076293945,59278,0.0,0.0,10.565999984741211,12.005599975585938,17.403100021680196,-1.3817897847634868,-11.99107078173714,-31.014589580995537,36.91920582312878,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-25,10.680000305175781,10.680000305175781,10.199999809265137,10.399999618530273,35845,0.0,0.0,10.523999977111817,11.888149976730347,17.274516685803732,-1.1782626268645628,-11.47487205569153,-31.180998039151646,36.73843152213758,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-28,10.979999542236328,10.979999542236328,10.399999618530273,10.5,39793,0.0,0.0,10.455999946594238,11.77504997253418,17.146850021680198,0.4208115305135776,-11.202075821475784,-31.328203386359597,38.36348923889999,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-29,10.5,10.5,10.239999771118164,10.479999542236328,32665,0.0,0.0,10.40399990081787,11.672549962997437,17.019558358192445,0.7304848341307939,-10.867805802510441,-31.416845741013017,38.15239634272226,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-04-30,10.539999961853027,10.539999961853027,9.949999809265137,9.949999809265137,34878,0.0,0.0,10.328999900817871,11.569199967384339,16.897391684850056,-3.6692815876852194,-10.719842945603977,-31.532628330104302,32.974491926045204,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-02,10.100000381469727,10.300000190734863,9.979999542236328,10.279999732971191,180273,0.0,0.0,10.336999893188477,11.47284996509552,16.781975022951762,-0.551418794681861,-9.900330566186277,-31.635877485190218,38.565232015253514,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-05,10.5,10.5,10.180000305175781,10.279999732971191,38633,0.0,0.0,10.354999828338624,11.37614996433258,16.671016693115234,-0.7242887166659231,-8.976236593184408,-31.76091072459497,38.565232015253514,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-06,10.220000267028809,10.979999542236328,9.600000381469727,9.720000267028809,315050,0.0,0.0,10.308999824523926,11.276749968528748,16.560516699155173,-5.713450068104139,-8.581817870446953,-31.905808415361665,33.12703545911562,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-07,9.899999618530273,9.970000267028809,9.3100004196167,9.430000305175781,63960,0.0,0.0,10.235999870300294,11.180299973487854,16.4458083709081,-7.874165448781574,-8.446107040301282,-32.01732793344896,30.711801247067598,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-08,9.65999984741211,9.869999885559082,9.399999618530273,9.600000381469727,40394,0.0,0.0,10.105999946594238,11.10259997844696,16.334100047747295,-5.006922301588133,-8.97627613160325,-32.02808880812404,33.7606011409424,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-09,9.6899995803833,9.800000190734863,9.5,9.800000190734863,24495,0.0,0.0,10.04399995803833,11.041349983215332,16.2258083820343,-2.4293087248391676,-9.032863071029693,-31.951926688345196,37.25836609622733,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-12,9.800000190734863,9.800000190734863,9.5,9.600000381469727,23638,0.0,0.0,9.964000034332276,10.983500003814697,16.124933385848998,-3.6531478483374222,-9.282104694572196,-31.88498990356355,35.253605736946795,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-13,9.699999809265137,10.0600004196167,9.520000457763672,9.800000190734863,146692,0.0,0.0,9.894000053405762,10.939800000190735,16.01993339061737,-0.9500693568173303,-9.559589268238353,-31.711326548973002,38.79990545114432,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-14,9.800000190734863,10.260000228881836,9.699999809265137,10.0,123181,0.0,0.0,9.84600009918213,10.899799990653992,15.928266723950705,1.564085915768607,-9.66806631658784,-31.5694533526087,42.208745732515375,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-15,10.800000190734863,10.800000190734863,9.520000457763672,10.199999809265137,29531,0.0,0.0,9.87100009918213,10.86344997882843,15.840225060780844,3.3329926732577646,-9.135678643345049,-31.41858820096261,45.47915298839088,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-16,10.300000190734863,10.34000015258789,9.949999809265137,9.960000038146973,30292,0.0,0.0,9.839000129699707,10.802449989318848,15.754683391253154,1.2297988296800466,-8.918808794039986,-31.433404778440277,42.37984317000872,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-19,9.960000038146973,10.199999809265137,9.569999694824219,9.920000076293945,12838,0.0,0.0,9.803000164031982,10.727449989318847,15.675983389218649,1.193511275162944,-8.617610207526726,-31.56761063744949,41.86773055052628,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-20,9.930000305175781,10.760000228881836,9.930000305175781,10.5600004196167,110742,0.0,0.0,9.887000179290771,10.679550004005431,15.596108388900756,6.806920482671669,-7.421191196421287,-31.524264017004906,51.88581292249352,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-21,10.960000038146973,10.960000038146973,10.239999771118164,10.699999809265137,45940,0.0,0.0,10.014000129699706,10.637199997901917,15.521475052833557,6.850406138211242,-5.858683378380873,-31.467853656344218,53.76291705638251,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-22,16.239999771118164,18.479999542236328,15.0,17.0,2222082,0.0,0.0,10.754000091552735,10.771399998664856,15.496391717592875,58.080712807074434,-0.1615380276870077,-30.490915595298162,84.00468350480533,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-23,17.700000762939453,17.700000762939453,15.220000267028809,15.739999771118164,611788,0.0,0.0,11.348000049591064,10.869799995422364,15.462008388837178,38.702852505586385,4.399345474342553,-29.69994762601582,73.6318546464436,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-26,15.699999809265137,15.699999809265137,14.520000457763672,14.859999656677246,450257,0.0,0.0,11.873999977111817,10.941299986839294,15.420025046666463,25.14737818192022,8.524581095431238,-29.044862419308398,67.37456215092467,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-27,14.819999694824219,15.239999771118164,14.319999694824219,14.34000015258789,217294,0.0,0.0,12.32799997329712,11.00164999961853,15.374941714604695,16.320572547443497,12.055918646062896,-28.444281586004088,63.917966714634,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-28,14.520000457763672,15.0600004196167,14.100000381469727,14.5600004196167,139077,0.0,0.0,12.784000015258789,11.073150014877319,15.332975045839946,13.89236860323923,15.450436398701898,-27.782116766167817,64.7421306798256,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-05-30,14.699999809265137,15.479999542236328,14.520000457763672,15.119999885559082,145992,0.0,0.0,13.276000022888184,11.153750014305114,15.292308378219605,13.889724762667917,19.027233045937038,-27.063006196035914,66.81968420947894,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-02,15.079999923706055,15.180000305175781,14.279999732971191,14.9399995803833,70360,0.0,0.0,13.773999977111817,11.227250003814698,15.252158379554748,8.465221469500646,22.683648911637373,-26.38910687641016,65.48400639345473,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-03,14.920000076293945,15.300000190734863,14.680000305175781,15.0,64921,0.0,0.0,14.281999969482422,11.307750010490418,15.21880837281545,5.0273073242668405,26.30275657166753,-25.698847547822133,65.72991751664763,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-04,15.279999732971191,16.440000534057617,15.0,16.100000381469727,199492,0.0,0.0,14.835999965667725,11.425250029563903,15.187808378537495,8.519819484544687,29.852737815611796,-24.773543721361502,69.95600690265573,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-05,16.020000457763672,16.3799991607666,14.979999542236328,15.680000305175781,92813,0.0,0.0,15.33400001525879,11.54700002670288,15.15595837434133,2.2564255221904825,32.79639715768881,-23.81214211928906,66.57996144933429,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-09,18.0,18.8799991607666,17.34000015258789,18.139999389648438,574398,0.0,0.0,15.447999954223633,11.733500003814697,15.143475031852722,17.426200436314645,31.6572203451767,-22.517784199897957,74.37911760190123,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-10,18.5,18.979999542236328,17.31999969482422,17.459999084472656,236739,0.0,0.0,15.619999885559082,11.894499969482421,15.126475024223328,11.779764483959314,31.32119824822508,-21.366346419541017,69.54761980291232,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-11,17.459999084472656,17.920000076293945,16.899999618530273,17.760000228881836,71975,0.0,0.0,15.90999994277954,12.067999982833863,15.096266690889994,11.627908816818593,31.83626089998951,-20.059705952886826,70.45931529770411,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-12,17.799999237060547,18.479999542236328,17.360000610351562,17.700000762939453,54423,0.0,0.0,16.246000003814697,12.230999994277955,15.049266695976257,8.949900029443217,32.82642475198336,-18.726937057018375,70.00789122136565,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-13,17.799999237060547,18.34000015258789,17.299999237060547,17.520000457763672,122681,0.0,0.0,16.542000007629394,12.394000005722045,14.990850027402242,5.9122261496990145,33.467807003326655,-17.32290041547567,68.5881604519042,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-16,17.700000762939453,18.860000610351562,17.700000762939453,18.600000381469727,217054,0.0,0.0,16.89000005722046,12.59150002002716,14.949183360735576,10.124335810870793,34.1381092829004,-15.771318632032658,72.22740045446646,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-17,18.799999237060547,18.940000534057617,17.860000610351562,17.899999618530273,51538,0.0,0.0,17.186000061035156,12.784000015258789,14.913475028673808,4.154541807048684,34.43366740083078,-14.278865316907863,66.82351522209522,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-18,17.84000015258789,17.84000015258789,16.700000762939453,16.899999618530273,109105,0.0,0.0,17.376000022888185,12.953999996185303,14.87535002231598,-2.73941300489704,34.13617437088987,-12.916334897990769,59.92581591179309,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-19,16.719999313354492,17.079999923706055,16.479999542236328,16.579999923706055,46127,0.0,0.0,17.423999977111816,13.11399998664856,14.8451833486557,-4.843893793126954,32.865639735025866,-11.661582894251737,57.86735410469792,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-23,16.600000381469727,16.6200008392334,15.800000190734863,16.200000762939453,52328,0.0,0.0,17.476000022888183,13.265000009536744,14.816366680463155,-7.30143773333465,31.74519419769304,-10.470628220696248,55.432295177982645,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-24,16.020000457763672,16.600000381469727,16.020000457763672,16.079999923706055,71287,0.0,0.0,17.270000076293947,13.394500017166138,14.78124167919159,-6.89056252073428,28.93351789287425,-9.381767053965762,54.650210072764956,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-25,16.059999465942383,16.520000457763672,15.720000267028809,15.739999771118164,82714,0.0,0.0,17.098000144958498,13.527500009536743,14.745325016975404,-7.94245152840727,26.394382797298764,-8.259058420459722,52.39463401037666,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-26,15.739999771118164,16.260000228881836,15.4399995803833,16.200000762939453,92536,0.0,0.0,16.94200019836426,13.672500038146973,14.709491689999899,-4.379644827866577,23.912965083892583,-7.049812962319522,55.09501203484861,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
2025-06-27,16.1200008392334,16.260000228881836,15.699999809265137,16.040000915527344,69995,0.0,0.0,16.776000213623046,13.811000061035156,14.664991704622905,-4.3872155980185905,21.468395767754846,-5.823335333483631,53.948719972135216,,,0.0,1.0,-0.83217,0.075,1.4589777,-1.8457999,Cinclus Pharma Holding AB (publ),Healthcare,"Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden."
